|In adults receiving treatment with a biologic, we conditionally recommend against discontinuation of the biologic.|Low|79|
|In adults receiving treatment with a biologic, we conditionally recommend against tapering of the biologic dose as a standard approach.|Very low|78|
|In adults receiving treatment with an originator TNFi, we strongly recommend continuation of treatment with the originator TNFi over mandated switching to its biosimilar.|Very low|76|